FDA Approves Indian Drug Maker’s Diabetes Drug Trial

7142

The drug discussed below is for the treatment of type 2 diabetes.

The Food and Drug Administration has given Cadila Healthcare the go-ahead to conduct U.S. trials of its ZYGK1 drug for treating diabetes.

Cadila is a pharmaceutical company based in Ahmedabad, in India’s Gujarat state. The firm does business in 90 countries.

ZYGK1 is an orally administered drug that acts as a glucose sensor in the pancreas and regulates glucose metabolism in the liver. It is considered a “new molecular entity,” a chemical that has not been seen before in drugs. Because of its newness, an NME undergoes particularly intense scrutiny to prove its effectiveness and safety.

At this time, neither Cadila nor the FDA has given specifics about how the U.S. tests will proceed.

 

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.